Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

被引:50
|
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Kwon, Mi [3 ]
Perez, Ariadna [4 ]
Parody, Rocio [5 ]
Ferra, Christelle [6 ]
Garcia Cadenas, Irene [1 ]
Herruzo, Beatriz [2 ]
Dorado, Nieves [3 ]
Hernani, Rafael [4 ]
Sanchez-Ortega, Isabel [5 ]
Torrent, Anna [6 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Gregorio Maranon, Hematol Dept, Madrid, Spain
[4] Hosp Clin Univ, Hematol Dept, Madrid, Spain
[5] Bellvitge Hosp, Hematol Dept, Barcelona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; RISK-FACTORS; HEMATOLOGIC MALIGNANCIES; HEMORRHAGIC CYSTITIS; ACUTE-LEUKEMIA; BACTEREMIA; OUTCOMES; DONORS; ADULTS;
D O I
10.1038/s41409-021-01328-4
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in 11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM was 3 months (range 1-30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years, lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM (51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
引用
收藏
页码:2432 / 2444
页数:13
相关论文
共 50 条
  • [31] Peripheral Blood Stem Cells for T Cell-Replete Nonmyeloablative Hematopoietic Transplants Using Post-Transplant Cyclophosphamide
    Bashey, Asad
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (05) : 598 - 599
  • [32] Post-transplant cyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
    Borovkova, Anastasya Svyatoslavovna
    Paina, Olesya Vladimirovna
    Semenova, Elena Vladimirovna
    Bykova, Tatiana Alexandrovna
    Osipova, Anna Alekseevna
    Slesarchuk, Olga Alexandrovna
    Kozhokar, Polina Valerievna
    Tsvetkova, Lubov Alexandrovna
    Rakhmanova, Zhemal Zarifovna
    Kozlov, Andrei Vadimovich
    Chukhlovin, Alexei Borisovich
    Kazantsev, Ilya Viktorovich
    Estrina, Maria Arkadievna
    Goloshchapov, Oleg Valerievich
    Bondarenko, Sergei Nikolaevich
    Moiseev, Ivan Sergeevich
    Kulagin, Alexander Dmitrievich
    Zubarovskaya, Ludmila Stepanovna
    CLINICAL TRANSPLANTATION, 2024, 38 (01)
  • [33] Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide
    Oostenbrink, Lisa V. E.
    Pool, Emma S.
    Jol-van der Zijde, Cornelia M.
    Jansen-Hoogendijk, Anja M.
    Vervat, Carly
    van Halteren, Astrid G. S.
    Bredius, Robbert G. M.
    Smiers, Frans J. W.
    van Tol, Maarten J. D.
    Schilham, Marco W.
    Lankester, Arjan C.
    Mohseny, Alexander B.
    BONE MARROW TRANSPLANTATION, 2021, 56 (09) : 2203 - 2211
  • [34] An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide
    Shabbir-Moosajee, Munira
    Lombardi, Lindsey
    Ciurea, Stefan O.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 541 - 548
  • [35] Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
    Kwon, M.
    Bautista, G.
    Balsalobre, P.
    Sanchez-Ortega, I.
    Montesinos, P.
    Bermudez, A.
    de Laiglesia, A.
    Herrera, P.
    Martin, C.
    Humala, K.
    Zabalza, A.
    Torres, M.
    Bento, L.
    Corral, L. L.
    Heras, I.
    Serrano, D.
    Buno, I.
    Anguita, J.
    Regidor, C.
    Duarte, R.
    Cabrera, R.
    Gayoso, J.
    Diez-Martin, J. L.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1138 - 1143
  • [36] Pediatric unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and reduced intensity, TBI-free conditioning regimens in salvage transplantations
    Wawrzyniak-Dzierzek, Elzbieta
    Gajek, Kornelia
    Slezak, Aleksandra
    Rybka, Blanka
    Ryczan-Krawczyk, Renata
    Gorczynska, Ewa
    Kalwak, Krzysztof
    Ussowicz, Marek
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (09): : 1223 - 1228
  • [37] Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide
    Sugita, Junichi
    Kagaya, Yusuke
    Miyamoto, Toshihiro
    Shibasaki, Yasuhiko
    Nagafuji, Koji
    Ota, Shuichi
    Furukawa, Tatsuo
    Nara, Miho
    Akashi, Koichi
    Taniguchi, Shuichi
    Harada, Mine
    Matsuo, Keitaro
    Teshima, Takanori
    BONE MARROW TRANSPLANTATION, 2019, 54 (03) : 432 - 441
  • [38] Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
    Otoukesh, Salman
    Elmariah, Hany
    Yang, Dongyun
    Clark, Mary C.
    Siraj, Madiha
    Ali, Haris
    Mogili, Krishnakar
    Arslan, Shukaib
    Nishihori, Taiga
    Nakamura, Ryotaro
    Pidala, Joseph
    Marcucci, Guido
    Forman, Stephen J.
    Anasetti, Claudio
    Al Malki, Monzr M.
    Bejanyan, Nelli
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (02): : 111.e1 - 111.e8
  • [39] Feasibility of HLA-Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Advanced Pediatric Malignancies
    Sawada, Akihisa
    Shimizu, Mariko
    Isaka, Kanako
    Higuchi, Kouhei
    Mayumi, Azusa
    Yoshimoto, Yuri
    Kikuchi, Hiroaki
    Kondo, Osamu
    Koyama-sato, Maho
    Yasui, Masahiro
    Kawa, Keisei
    Inoue, Masami
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (08) : 754 - 764
  • [40] Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia
    Arcuri, Leonardo Javier
    Nabhan, Samir Kanaan
    Cunha, Renato
    Nichele, Samantha
    Feitosa Ribeiro, Andreza Alice
    Fernandes, Juliana Folloni
    Daudt, Liane Esteves
    Melo Rodrigues, Ana Luiza
    Arrais-Rodrigues, Celso
    Seber, Adriana
    Atta, Elias Hallack
    Rodrigues de Oliveira, Jose Salvador
    Moreira Funke, Vaneuza Araujo
    Loth, Gisele
    Darrigo Junior, Luiz Guilherme
    Paz, Alessandra
    Calixto, Rodolfo Froes
    Gomes, Alessandra Araujo
    Sa Araujo, Carlos Eduardo
    Colturato, Vergilio
    Simoes, Belinda Pinto
    Hamerschlak, Nelson
    Flowers, Mary Evelyn
    Pasquini, Ricardo
    Rocha, Vanderson
    Bonfim, Carmem
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) : 2311 - 2317